HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Diana Wu provides a review of several concepts related to the physiology of pediatric malignancies and survivorship that will help introduce the material in the rest of this module. Topics include the results of advancements in diagnostic and risk-adapted treatment modalities, the four subgroups of acute medulloblastoma leukemia, and the social risks and needs of a growing population of survivors.

 

In this episode you will learn:

 

Pediatric Malignancies and Survivorship Fundamentals

• The two main factors that affect the risk stratification and prognosis in pediatric acute lymphoblastic leukemia
• Patient-related and cytogenetic factors that affect risk stratification and prognosis
• The four subgroups of acute medulloblastoma leukemia that affect prognosis and possible targeted treatment options
• An overview of the common staging and unique qualifications of neuroblastoma
• Characteristics and categories of high-grade childhood non-Hodgkin’s lymphoma
• The resulting needs and risk advancements in diagnostic and risk-adapted treatment modalities

 

Mentioned in This Episode:

HOPA

 

Quotes:

 

“Recently, the recognition of the subgroups based on molecular markers is beginning to change the treatment of childhood medulloblastoma.” — Dr. Diana Wu

 

“Screening for neuroblastoma is not recommended in the general population even though a potentially viable screening marker does exist.” — Dr. Diana Wu

 

“Advancements in diagnostic and risk-adapted treatment modalities have significantly improved survival in pediatric malignancies, creating a growing population with unique health and psychosocial risks and needs.” — Dr. Diana Wu